News | Implantable Cardiac Monitor (ICM) | July 01, 2019

Biotronik Launches Biomonitor III Injectable Cardiac Monitor in Europe

Next-generation ICM makes injection, monitoring and diagnosis of arrhythmias easy and efficient

Biotronik Launches Biomonitor III Injectable Cardiac Monitor in the CE Region

July 1, 2019 – Biotronik announced the European market release of its new injectable cardiac monitor (ICM), Biomonitor III, following CE mark approval. The novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhythmia or unexplained syncope with increased clarity.

As the most common type of arrhythmia, 33.5 million patients worldwide suffer from atrial fibrillation (AF).1 It is associated with a five-fold increase in risk of stroke, a three-fold increase in incidence of congestive heart failure and higher mortality.2 Aiming to improve the accuracy of arrhythmia detection and diagnosis, Biotronik’s new ICM offers increased signal quality.3

“What I like about Biomonitor III is the ease of use and the high signal fidelity,” said Associate Prof. Paul Gould, cardiologist and electrophysiologist at St Andrew’s War Memorial Hospital, Brisbane, Australia. “This coupled with the automatic Home Monitoring provides an excellent resource to establish a rhythm symptom correlation or to detect occult arrhythmias in my patients." 

Biomonitor III’s BIOvector technology is designed to deliver high-definition signals. As a result, the high signal amplitudes and visibility of the p-waves3 make it easier for the physician to confidently evaluate arrhythmias. 

Biotronik’s next-generation ICM is 60 percent smaller than its predecessor, BioMonitor 2, and comes ready to inject, with the device pre-assembled in a one-piece injection tool. To optimize patient comfort, Biomonitor III offers a very small size and flexible sensing antenna. The device is injected under the skin with a very small incision, facilitating in-office treatments. 

The device works with Biotronik’s fully automated, ‘plug in and go’ Home Monitoring. Due to automatic pairing, initialization and data transmission, no active patient involvement is required. The new product also features Intelligent Memory Management, which prevents the overwriting of clinically relevant episodes. Thus, no relevant information is missed.

For more information: www.biotronik.com

 

References

1. Chugh S.S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation, 129 (2014):837-847.

2. Camm A.J. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.

3. BIO|CONCEPT.BIOMONITOR III Study. Data on file.

Related Content

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath
Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020
January 31, 2020 – The U.S.
Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...